EQS-News

Formycon invites to the Annual General Meeting on June 12, 2024 in Munich - Seite 2

The previously elected Supervisory Board members Wolfgang Essler, General Authorized Representative of ATHOS KG, and Klaus Roehrig, Founding Partner of the Active Ownership Group AOC, will continue their duties. Wolfgang Essler has agreed to take over as Chairman of the Supervisory Board following the election of the new Supervisory Board by the Annual General Meeting. 

Dr. Olaf Stiller, Acting Chairman of the Supervisory Board, commented on his decision to support and initiate the more international approach and the expansion of the Supervisory Board: "Formycon has made impressive progress in recent years and is on track for expansion with a growing and sustainable biosimilar pipeline. Now, it is the right time to pass the baton to new hands. I co-founded the company, have actively supported it for a long time and will remain closely associated with it as I am very proud of this great company with its experienced and strong team". 

Peter Wendeln, Deputy Chairman of the Supervisory Board, said: "As an investor from the very beginning and today Formycon’ s second largest shareholder, I am very interested in ensuring that the path we have taken, and the greater internationalization of the business are successful. In addition to strong partners in manufacturing and commercialization, it is important to have an internationally focused management and Supervisory Board team with a strong sector network and financial expertise, and to adapt and strengthen this team in line with the company's development. Like Dr. Olaf Stiller, I will remain closely associated with Formycon and proudly follow its further development."

Stefan Glombitza, CEO of Formycon AG, commented: "The biosimilars market will grow rapidly in the coming years. The development and commercialization of biosimilars will enable us to achieve our mission of providing high-quality medicines. The entire Management Board of Formycon AG and its employees are extremely committed to this task and are working with great passion to lead Formycon into a promising and profitable future. We would like to thank Dr. Olaf Stiller and Peter Wendeln from the bottom of our hearts for their tireless commitment to Formycon as Supervisory Board members, for their strategic vision as investors and for the great support that my colleagues and I have received over the years. As Management, we welcome the new suggestions for the Supervisory Board and its expansion to five members and hope for the approval of our Annual General Meeting."